TY - JOUR T1 - Costs and health-related quality of life in COPD patients with α-1-antitrypsin deficiency: results of the COSYCONET cohort JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/1393003.congress-2017.PA1199 VL - 50 IS - suppl 61 SP - PA1199 AU - Margarethe E. Wacker AU - Florian M. Karl AU - Rolf Holle AU - Robert Bals AU - Timm Greulich AU - Rudolf A. Jörres AU - Annika Karch AU - Stefan Karrasch AU - Armin Koch AU - Reiner Leidl AU - Holger Schulz AU - Claus Vogelmeier Y1 - 2017/09/01 UR - http://erj.ersjournals.com/content/50/suppl_61/PA1199.abstract N2 - Background: COPD is a costly disease. However, there is lack of evidence on differences in costs and health-related quality of life (HRQL) between COPD patients with and without a-1-antritrypsin deficiency (AATD).Methods: 131 COPD patients with AATD (106 with augmentation therapy (AT)) and 2,049 COPD patients without AATD participating in the baseline visit of the German COSYCONET cohort were compared. Information on healthcare utilization, work absence and premature retirement was used to calculate societal costs in the year 2012. HRQL was assessed by the CAT, SGRQ and the generic EQ-5D-3L questionnaire. The association of AATD (with/without AT) with costs and HRQL was analysed by generalized linear regression models controlling for GOLD grade, age, sex, education, smoking status, BMI and comorbidity as potential confounders.Results: Adjusted annual mean healthcare costs were €6.099 for AATD patients without AT, €7.117 for AATD patients with AT (excluding costs of AT, €70K per year) and €7.460 for COPD patients without AATD. Augmented AATD patients showed significantly higher outpatient (+270%), but lower inpatient costs (-35%) compared to COPD patients without AATD. The group of AATD patients had lower medication costs (-28%) than the control group (excluding costs of AT). Costs for work absence/ retirement and generic/COPD-specific HRQL scores did not differ between groups.Conclusion: Apart from the high costs of AT, COPD patients with AATD showed slightly lower healthcare costs than COPD patients without AATD in this cross-sectional analysis. To provide conclusive arguments in the controversy about the cost-effectiveness of AT, longitudinal data are needed ER -